

Applicants: Yuan Chang and Patrick S. Moore  
Serial No.: 10/656,499  
Filed: September 5, 2003  
Page 3

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1-47. (Canceled)

48. (Currently Amended) An isolated antibody ~~capable of specifically binding which binds~~ to an isolated polypeptide comprising consecutive amino acids having the sequence set forth in SEQ ID NO:2, or a fragment thereof, encoded by a nucleic acid which encodes a Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 2 polypeptide or a fragment thereof.

49. (Currently Amended) ~~An~~ The antibody of claim 48, wherein the antibody is a monoclonal antibody.

50. (Original) The antibody of claim 48, wherein the antibody is a polyclonal antibody.

51. (Original) The antibody of claim 48, wherein the antibody is humanized.

52. (Original) The antibody of claim 48, wherein the antibody is detectable.

53. (Original) The antibody of claim 52, wherein the detectable antibody is labeled with a detectable marker.

54. (Currently Amended) The labeled antibody of claim 53, wherein the detectable marker is a radioactive label or a ~~calorimetric~~ colorimetric, or a luminescent, or a

Applicants: Yuan Chang and Patrick S. Moore  
Serial No.: 10/656,499  
Filed: September 5, 2003  
Page 4

fluorescent marker.

55. (Original) A composition comprising the antibody of claim 48 and an agent conjugated to the antibody.
56. (Original) The composition of claim 55 wherein the agent is a radioactive isotope or toxin.
57. (Currently Amended) A method of determining whether a subject is afflicted with a disease associated with Kaposi's sarcoma-associated herpesvirus infection of a B cell which comprises:
  - (a) obtaining a suitable sample from the subject;
  - (b) contacting the suitable sample with the detectable antibody of claim 52 so as to form a complex between the antibody and any Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 2 polypeptide comprising consecutive amino acids having the sequence set forth in SEQ ID NO:2, or a fragment thereof, present in the sample;
  - (c) removing any unbound antibody; and
  - (d) detecting any antibody which is bound to any Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 2 in the sample, wherein the presence of bound antibody indicates that the subject is afflicted with the disease.
58. (Original) The method of claim 57, wherein the disease is Castleman's disease.
59. (Original) The method of claim 57, wherein the disease is

Applicants: Yuan Chang and Patrick S. Moore  
Serial No.: 10/656,499  
Filed: September 5, 2003  
Page 5

Primary Effusion Lymphoma.

60. (Currently Amended) A method of determining whether a subject is afflicted with a disease associated with Kaposi's sarcoma-associated herpesvirus infection of a B cell which comprises:

- (a) obtaining a suitable sample from the subject;
- (b) immobilizing a an isolated capturing antibody to a support, wherein the capturing antibody is capable of binding to Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 2 polypeptide comprising consecutive amino acids having the sequence set forth in SEQ ID NO:2, or a fragment thereof to a support;
- (c) removing any unbound capturing antibody;
- (d) contacting the immobilized capturing antibody with the suitable sample so as to form a complex between the antibody and any Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 2 polypeptide or fragment thereof present in the sample;
- (e) removing any unbound sample;
- (f) contacting ~~the~~ any complex obtained in step (d) with the detectable antibody of claim 52 so as to form a complex between the detectable antibody and the complex;
- (g) removing any unbound detectable antibody; and
- (h) detecting any detectable antibody which is bound to

Applicants: Yuan Chang and Patrick S. Moore  
Serial No.: 10/656,499  
Filed: September 5, 2003  
Page 6

the complex wherein the presence of detectable antibody indicates that the subject is afflicted with the disease.

61. (Original) The method of claim 57, wherein the disease is Castleman's disease.

62. (Original) The method of claim 57, wherein the disease is Primary Effusion Lymphoma.

63-91. (Canceled)

92. (Original) A composition comprising the antibody of claim 48 and a carrier.

93. (Currently Amended) A method of treating a subject infected with Kaposi's sarcoma-associated herpesvirus, which comprises administering to the subject an amount of the composition of claim 92 under conditions such that the antibody binds to any Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 2 polypeptide comprising consecutive amino acids having the sequence set forth in SEQ ID NO:2, or a fragment thereof, present in the subject, so as to thereby treat the subject.

94. (Canceled)